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Abstract:  25 
Purpose: To determine if (1) Human L-PRP or (2) L-PRF delivered on a HA scaffold at a bovine 26 
chondral defect, a simulated cartilage tear interface, in vitro would improve tissue formation 27 
based on biomechanical, histological, and biochemical measures.  28 
Methods: L-PRF and L-PRP was prepared from 3 healthy volunteer donors which was delivered 29 
in conjunction with Hyaluronic acid (HA scaffolds) to defects created in full thickness bovine 30 
cartilage plugs harvested from bovine femoral condyle and trochlea. Specimens were cultured in 31 
vitro for up to 42 days. Treatment groups included an HA scaffold alone and scaffolds containing 32 
L-PRF or L-PRP. Cartilage repair was assessed using biomechanical testing, histology, DNA 33 
quantification, and measurement of sulfated glycosaminoglycan (sGAG) and collagen content at 34 
28 and 42 days. 35 
Results: L-PRF elicited the greatest degree of defect filling and improvement in other 36 
histological measures. L-PRF treated specimens also h d the greatest cellularity when compared 37 
to L-PRP and control at day 28 (560.4 vs. 191.4 vs. 124.2, p=00.15); at day 48 there remains a 38 
difference though not significant between L-PRF vs L-PRP, (761.1 vs 589.3, p=0.219) . L-PRF 39 
had greater collagen deposition when compared to L-PRP at day 42 (40.1 vs 16.3, p< 0.0001). L-40 
PRF had significantly higher maximum interfacial strength compared to the control at day 42 41 
(10.92 N vs 0.66 N, p=0.015), but had no significant difference compared to L-PRP (10.92 N vs 42 
6.58, p=0.536).   L-PRP facilitated a greater amount f sGAG production at day 42 when 43 
compared to L-PRF (15.9 vs. 4.3, p=0.009). 44 
Conclusions: Delivery of leukocyte rich platelet concentrates in conjunction with a HA scaffold 45 
may allow for improvements in cartilage healing through different pathways. L-PRF was not 46 
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superior to L-PRP in its biomechanical strength suggesting that both treatments may be effective 47 
in improving biomechanical strength of healing cartil ge through different pathways. 48 
 49 
Statement of Clinical Relevance: The delivery of platelet-rich concentrates in conjunction HA 50 
scaffolds may augment healing cartilaginous injuries.  51 
  52 
 Keywords: cartilage repair,  PRP, leukocyte-rich platelet-rich fibrin, leukocyte rich 53 
platelet enriched concentrates  54 
 55 
Introduction 56 
Focal cartilage defects may be caused by sports injury, trauma, and other activities of daily 57 
living1. As cartilage has limited capacity for intrinsic repair, such defects often further 58 
degenerate, progressing into osteoarthritis with associated symptoms of pain, swelling, and 59 
stiffness1,2. There are few effective treatments for articular c tilage injuries. Previous efforts 60 
have used cell-based therapies (autologous chondrocyte implantation, matrix-induced autologous 61 
chondrocyte implantation, bone marrow and adipose-derived stem cells), microfracture, and 62 
cytokines to promote cartilage repair; however, these attempts have not achieved ideal 63 
osteochondral defect repair with regeneration of morph logically similar hyaline cartilage 64 
tissue3.Autologous chondrocyte implantation as well as matrix-induced autologous chondrocyte 65 
implementation has been shown improved clinical outc mes, however its cost is high, and the 66 
procedure to obtain the cartilage pieces is invasive3,4. These cells can produce hyaline cartilage, 67 
however, this procedure is also associated with the formation of fibrocartilage, which typically 68 
occurs secondary to de-differentiation of chondrocytes during cell expansion after harvest3.   69 
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Mesenchymal stem cells harvested from bone marrow o adipose tissue have been shown to give 70 
rise to a mixture of hypertrophic, cartilaginous, and fibrous tissues and can lead to loss of tissue 71 
in the long run3,5. Microfracturing has been shown to significantly improve the symptoms of 72 
patients and is thought to bring about the recruitment of mesenchymal stem cells, it is only 73 
effective for small defects and has been shown to only have a short-term functional improvement 74 
due to the formation of fibrocartilage rather than hyaline articular cartilage3,6.   75 
 76 
The use of scaffolds is promising as a viable surgical option in cartilage repair1,7. Scaffolds can 77 
augment cell migration from the surrounding tissue, stimulate cell proliferation, and aid in 78 
maintenance of cell phenotype in order to facilitate regeneration of functional tissue7,8. 79 
Specifically, hyaluronic acid  (HA) scaffolds may facilitate cellular migration by providing both 80 
biochemical and biophysical cues improving articular c rtilage repair9,10. HA scaffolds have been 81 
shown to increase early-stage gene expression of SOX-9 and collagen type II as well as cartilage 82 
matrix production11. Although HA has been found to be useful in reducing pain and symptoms 83 
and recovering articular function, Kon et al. found that autologous platelet rich concentrates 84 
showed more and longer efficacy than HA, suggesting that using HA scaffold alone may have 85 
limited therapeutic effects12.  86 
 87 
Platelet-rich concentrates have been proposed to improve healing of different tissues due to their 88 
abundance of growth factors and cytokines. Platelet-rich plasma (PRP) and platelet-rich fibrin 89 
(PRF) have both been shown to promote the repair of articular cartilage defects4,13,14. PRP is a 90 
concentrate of platelet-rich plasma derived from whole blood, centrifuged to reduce the number 91 
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of red blood cells in a liquid form, whereas PRF is composed of autologous platelets which are 92 
present in a complex stable fibrin matrix (gel-like consistency).  93 
 94 
There is significant variability in the methods of preparation and composition of platelet-rich 95 
concentrates15-17. Previous studies that have evaluated platelet-rich concentrates have used a 96 
variety of protocols for preparation of platelet-rich concentrates with variation in initial blood 97 
volume, velocity and time of centrifugation, number of centrifugation cycles, and inclusion or 98 
exclusion of leukocytes, which can alter the effect on tissue repair by changing its composition18. 99 
Specifically, platelet-rich concentrates with different compositions have different contents of 100 
growth factors and numerous other plasma proteins, which may alter its efficacy19,20. The 101 
optimal preparation method of platelet-rich concentrates has not yet been identified, and will 102 
likely differ for various tissues and pathologies. Leukocyte-platelet-rich concentrates have been 103 
shown to contain higher levels of growth factors and cytokines, as well as inflammatory 104 
cytokines that may have a catabolic effect, all of which is currently thought to be related to the 105 
presence of leukocytes21. Number of centrifugations of the whole blood has been found to alter 106 
the cytokine and growth factors release as well as the number of platelets, which has been found 107 
to be higher in double spin protocols to prepare PRP22-24. Leuckocyte-platelet-rich plasma (L-108 
PRP) have not been found to be effective in stimulating proliferation of new cartilage tissue25,26. 109 
It is not currently clear if L-PRF can consistently release growth factors given its 110 
microstructure22. Current literature is inconclusive as to the ability of L-PRP and L-PRF to 111 
improve cartilage integration23.  112 
 113 
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Both intraarticular injections of platelet rich concentrates and hyaluronic acid have been found 114 
independently to improve knee functional status and symptoms over time, however evidence of 115 
the superiority of one treatment over another remains mixed27-30. The combination of these two 116 
therapies (platelet-rich concentrates and HA scaffolds)may allow for optimized cytokine delivery 117 
of the platelet concentrates and promote tissue regneration by allowing cells to migrate into the 118 
scaffold, adhere, and produce new matrix to fill the defect. However, minimal research has been 119 
performed to investigate the use of scaffold materils in combination with platelet-rich 120 
concentrates to enhance cell migration. Therefore, the purpose of this study is to determine if (1) 121 
Human L-PRP or (2) L-PRF delivered on a HA scaffold at a bovine chondral defect, a simulated 122 
cartilage tear interface, in vitro would improve tissue formation based on biomechanical, 123 
histological, and biochemical measures. We hypothesized that the use of L-PRP and L-PRF in 124 
conjunction with an HA scaffold will improve biomechanical strength, improve cellular 125 
migration, have increased sulfated glycosaminoglycan (sGAG), and have increased collagen 126 
content when compared to an HA scaffold alone.  127 
 128 
 129 
Materials and Methods  130 
Preparation of the Cartilage Plugs:   131 
The explant model used in this study has previously been used to evaluate cartilage repair, 132 
scaffold integration, and cartilage interface development in vitro31. Three operators performed 133 
the specimen preparations. 24 full-thickness osteochondral plugs were harvested from a bovine 134 
femoral condyle and trochlea in a sterile manner using a 7mm diameter osteochondral graft 135 
harvester (single use OATS set 7mm, Arthrex, Naples, Fl, USA). The diameter of these plugs 136 
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were 7mm and thickness was 2.5mm. Osteochondral plugs were kept in Advanced DMEM 137 
(ADMEM)/F12 with 100 nM dexamethasone, 50 µg/mL ascorbate-2-phosphate, and 138 
penicillin/streptomycin (Life Technologies, Carlsbad, CA) within 5% CO2 and air-humidified 139 
incubator at 37 degrees Celsius for 6 hours. They wre then washed briefly using phosphate-140 
buffered saline and antibiotics – (penicillin/streptomycin, Life Technologies, Carlsbad, CA). A 141 
5.5mm diameter biopsy punch was used to create a circular defect through the center of the 142 
explant (the defect had a diameter 5.5mm and a depth of 2.5mm) to allow for a press fit of a 143 
6mm diameter scaffold with a thickness of 2.5mm placed within the core. Figure 1, Figure 2A, 144 
Figure 2B). 145 
 146 
Preparation of HA Scaffolds:  147 
HA scaffolds (Hyalofast, USA) were used for this study. The scaffolds were punched out using 148 
sterile 6 mm biopsy punches (McKesson, San Francisco, USA). The size of the scaffolds was 0.5 149 
mm larger than the diameter of the cartilage defect to allow for a press-fit. The thickness of the 150 
scaffold was the same as the plug, 2.5mm.  151 
 152 
Groups and Timepoints: 153 
Eight specimens were used at each time point in each group: Six for biomechanical testing of 154 
interface strength and biochemical analysis of DNA, collagen, and sGAG content, and two 155 
specimens used for histology (total number of specim ns: 24). The specimen test and timepoint 156 
allocation was determined at the time of preparation.  The specimens used for biomechanical 157 
testing were processed for biochemical evaluation after the biomechanical testing was complete. 158 
Biochemical testing was done on specimens from days 28 and 42 as we expected the largest 159 
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differences between groups at these time points. The early (28 day) time-point was chosen based 160 
on prior studies indicating that improvements in fuctional properties can be seen as early as 28 161 
days26. The later time point was selected as we expected th re to be greater differences between 162 
groups over time.  163 
 164 
Blood Collection:  165 
L-PRP and L-PRF was produced from blood samples from three fasting healthy male human 166 
donors after they provided informed consent (averag age: 34.6, range: 27-39). In each subject a 167 
total of 37mL of peripheral venous blood was collected in order to prepare the two platelet 168 
concentrates.  From these 37mL of whole blood, 1 mL was used to measure platelet- and 169 
leukocyte-counts with a cell counter Sysmex KX-21N (Sysmex-Suisse AG, Horgen, 170 
Switzerland). Of the addition 36 mL, 27 mL of the blood was collected in a 30-mL syringe 171 
containing 3 mL of ACD-A to prepare the L-PRP and 9 mL was collected in 10-mL glass-coated 172 
to prepare the L-PRF.  In the whole blood specimen th  average number of platelets was 188.3 x 173 
103cells/ µL (± 19 x 103cells/ µL) ; and the average number of leukocytes wa 4.9 x 103cells/ µL 174 
(± 0.5 x 103cells/ µL).  This protocol was approved by the Institutional Review Board. 175 
 176 
L-PRP Preparation:  177 
Given that previous literature supports that double-centrifugation results in a greater number of 178 
platelets and growth factor release we opted to use a pr viously described double-centrifugation 179 
method20,22-24. 27 mL of the blood was collected in a 30-mL syringe containing 3 mL of ACD-A. 180 
The blood was separated into its different cell elements by centrifugation at 160 G for 20 minutes 181 
at room temperature (Beckman J-6M Induction Drive Centrifuge, Beckman Instruments Inc., 182 
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Palo Alto, CA, USA). This resulted into three basic components: an upper layer referred to as the 183 
supernatant that contains most platelets, an intermediate thin layer that is known as the buffy coat 184 
which is rich in white blood cells and some platelets, and a bottom layer that contains all the red 185 
blood cells.  A mark was made 6mm below the line that separated the red blood cell component 186 
from the buffy coat and the serum component. All of the content above this mark was removed 187 
in order to increase the total amount of platelets collected after the second centrifugation. The 188 
sample was then centrifuged again at 400 G for 15 minutes resulting in two components: the 189 
supernatant containing the serum, buffy coat containing the platelets and the leukocytes. The L-190 
PRP (approximately 2.7 ml) was separated out. Of this, 500 uL was taken to measure platelet- 191 
and leukocyte-counts with a cell counter Sysmex KX-21N (Sysmex-Suisse AG, Horgen, 192 
Switzerland). 193 
 194 
L-PRF Preparation:  195 
To prepare L-PRF, 9 mL of blood was collected in 10-mL glass-coated, plastic tubes 196 
(Vacutainer; BD Biosciences, Allschwil, Switzerland). Using a similar protocol performed by 197 
Schär et al., immediately after collection the blood was centrifuged at 400 x g for 12 minutes at 198 
room temperature using a table-top centrifuge specifically designed for this application (EBA 20; 199 
Andreas Hettich GmbH & Co KG, Tuttlingen, Germany)23. The L-PRF was then allowed to 200 
congeal on a sterilized custom draining system and was cored using a 6 mm biopsy punch, 201 
ensuring a consistent volume for each specimen (Figure 2C).   202 
 203 
Preparation of Test Groups:  204 
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The following groups were tested: (1) control group where only a HA scaffold was applied 205 
(Figure 2D), (2) L-PRP with HA scaffold (Figure 2E), (3) L-PRF with HA scaffold (Figure 206 
2F). In the L-PRP groups, the scaffold was soaked for 5 minutes, a time used by previous studies  207 
to ensure that PRP had been completely soaked up bythe scaffold, in 100uL of undiluted PRP at 208 
day 0 prior to being placed into the defect in the culture plates32,33 (Figure 2E). In the L-PRF 209 
groups, a 6mm biopsy punch of the L-PRF was carefully layered around the scaffold and then 210 
placed within a bovine cartilage defect in Corning plates taking care to ensure that the scaffold 211 
now layered with L-PRF had the same thickness of the defect of 2.5mm(Corning Inc, Corning, 212 
NY). There were 8 specimens per plate with a total f 3 plates per timepoint; specimens cultured 213 
on the same plate were in the same treatment group. Each dish was then filled with 30ml of 214 
media. Therefore, the initial PRP concentration was3% (amount of PRP/total media volume in 215 
the dish). In the control group, only a HA scaffold was placed in the defect. Scaffold–cartilage 216 
constructs were cultured in individually wells in culture media the consisted of 30 mL Advanced 217 
DMEM (ADMEM)/F12 with 100 nM dexamethasone, 50 µg/mL ascorbate-2-phosphate, and 218 
penicillin/streptomycin (Life Technologies, Carlsbad, CA) within 5% CO2 and air-humidified 219 
incubator at 37 degrees Celsius. Media was changed ev ry three days by replacing half of the 220 
media in the culture dishes for 28 days and 42 days, respectively. The primary outcome measure 221 
was interface strength assessed by a pushout test. The secondary outcome measurements 222 
included scaffold DNA content (picogreen assay, Invitrogen, Carlsbad, CA), scaffold sulfated-223 
glycosaminoglycan (sGAG) content (Dimethylmethylene Blue Assay described by Farndale et 224 
al.)34, collagen content (hydroxyproline assay described by Stegmann et al.)35, and histology. All 225 
biochemical tests were performed on the tissue formed at the scaffold-explant interface.  226 
 227 
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Biomechanical Testing 228 
The cartilage interface strength was determined using a push-out test.  A 2.75-mm stainless steel 229 
indenter applied load to the scaffold by advancing at 10 µm/s using a custom built compression 230 
testing system previously described by Ng et al.25. The test was considered completed when there 231 
was a consistent drop in force. The maximum load was recorded and normalized to the 232 
interfacial surface area for each sample to determine the maximum interfacial strength.  233 
 234 
Biochemical Analysis 235 
After biomechanical testing samples were digested in papain for analysis of DNA, sGAG, and 236 
collagen content. DNA content per specimen was determin d using the dsDNA Picogreen Assay 237 
(Molecular Probes, Eugene, OR). sGAG content was determined using the 1,9-238 
dimethylmethylene blue dye binding assay with chondr itin-6 sulfate as a standard20. Digested 239 
aliquots were also hydrolyzed for 16 h in 12 N HCl at 110°C, and the hydroxyproline (HP) 240 
content was quantified via colorimetric reaction with chloramine T (Sigma-Aldrich, St Louis, 241 
MO) and 4-Dimethylamino benzaldehyde (Sigma-Aldrich, St Louis, MO), against an HP 242 
standard curve35. 243 
  244 
Histological Analysis 245 
Histological analysis was undertaken to evaluate the scaffold–cartilage interface. The explants 246 
were fixed in neutral buffered formalin with 0.5% cetylpyridinium chloride for 4 hours at room 247 
temperature, washed briefly in phosphate-buffered saline (PBS) to remove residue formalin, 248 
cryoprotected in a 30% sucrose solution at 4oC overnight, incubated for 2 hours in 5% gelatin + 249 
5% sucrose embedding medium, and then embedded in the gelatin–sucrose medium. Blocks 250 
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were cut on a cryotome for histological analysis of interfacial sGAG deposition and cellular 251 
infiltration using Safranin-O/Fast Green histological stain. Slides were reviewed at a 252 
magnification of 10x. Consensus grading was done by two evaluators in a blinded fashion, with 253 
grading of surface regularity, cellularity, stain uptake, and adherence/bonding of the scaffold to 254 
adjacent cartilage.  255 
 256 
Statistical Analysis 257 
Two-way ANOVA was performed using Graphpad PRISM 6 software (GraphPad Software, Inc, 258 
San Diego, CA, USA, 2015) to compare different conditions, with Tukey’s post-hoc testing to 259 
identify differences between groups. Significance was set at p <0.05. 260 
 261 
Results:  262 
Blood Collection:  263 
The number of platelets within the L-PRP was 188.4 x 104cells/ µL, representing a 10-fold 264 
increase from the original blood specimens collected.  The average number of white blood cells 265 
was 15.5  x 103cells/ µL, which was a 3.2 fold increase from the original blood specimens 266 
collected.  The hematocrit value was 36, which was a 0.12 fold decrease from the original blood 267 
specimen collected.  We did not evaluate changes in cellular concentrations in L-PRF given its 268 
gelatinous form.  269 
 270 
Mechanical Strength of the Interface: 271 
Following 42 days in culture, L-PRF demonstrated a maximum interfacial strength was 272 
significantly greater than the control (10.92N±9.25 vs. 0.66N±0.35, p=0.015, Figure 3, Table 1). 273 
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L-PRF though did had higher mean interfacial strength compared to that of L-PRP it was not 274 
significantly different (10.92N ± 9.25 vs. 6.58N ±10.87 , p=0.536).  There were no significant 275 
differences seen at day 28 between L-PRF, L-PRP, and the control  (3.08N±1.23, 1.74N ±1.07, 276 
0.63N ±0.29 p = 0.055)  In all groups, the maximum interfacial strength increased at each time 277 
point, though not significantly.  278 
 279 
Biochemical Analysis:  280 
The number of cells and thus DNA content of the constructs varied between groups and with 281 
culture time (Figure 4). The L-PRF group had a significantly greater number of cells compared 282 
to the L-PRP and control groups at both 28 (560.5µg±142.6, 124.2µg±65.8, 191.4µg±44.6  283 
p<0.001, Table 1, Figure 4) and 42 days (761.1µg±270.7, 589.3µg±224.2, 296.4µg±101.8, p< 284 
0.01, Figure 4, Table 1). Across all groups the DNA content increased betwe n days 28 and 42, 285 
however only the L-PRP group had a significant increase (124.2µg±65.8µg vs. 286 
589.3µg±224.2µg, p=0.0004, Figure 4, Table 1).    287 
 288 
Across groups, the total sGAG production increased from day 28 to day 42 (Figure 5, Table 1). 289 
L-PRP had larger total sGAG production compared to L-PRF at 28 and 42 days, but only had a 290 
significantly greater amount at day 42 (4.3µg± 11.5 vs 11.6µg±7.2, p=0.0095, Figure 5, Table 291 
1).  292 
 293 
Hydroxyproline assay demonstrated significantly greater collagen content in the L-PRF group  294 
compared to the control group on day 28 (31.2µg±5.3 vs. 17.6µg± 7.5, p=0.017, Figure 6, Table 295 
1) , but not to the L-PRP treatment group on day 28(31.2µg±5.3 vs. 21.1µg±10.2, p=0.092, 296 
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Figure 6, Table 1). On day 42 there was a significant difference betwe n L-PRF and the control 297 
group (40.1µg±9.7 vs. 16.3µg± µg, 20.4µg±6.8 vs. p=0.0006, Figure 6, Table 1). There was no 298 
significant difference observed between L-PRP and the control group at either timepoint 299 
(21.1µg±10.2 vs. 17.6µg±7.5µg, p=0.723, 16.3µg±7.6 vs. 20.4µg±6.8, p=0.659, Figure 6, Table 300 
1).  301 
 302 
Histological evaluation: 303 
Most specimens had at least some positive staining for proteoglycans. In all groups the Safranin-304 
O staining increased from day 28 to day 42, suggesting increased cellular infiltration and 305 
increased proteoglycan synthesis as demonstrated by the intensity of the staining (Figure 7).  All 306 
the specimens started to form disorganized cartilage- ike tissue at the edge with ECM deposition 307 
with more apparent cellular integration and extracellular matrix deposition at the edges of the 308 
construct  in the L-PRP and L-PRF groups. At the int rface of the L-PRP group, lacuna 309 
structures, typical of cartilage, are observed at the interface. There was more intense Safranin-O 310 
staining in the L-PRF and L-PRP groups compared to control on day 42. The L-PRP group had 311 
the most intense staining of Safranin-O on day 42.  312 
 313 
Discussion:  314 
The two principal findings of our study are that L-PRF elicited the greatest degree of cellularity, 315 
collagen production, while L-PRP facilitated the gratest amount of sGAG production. There 316 
was no superiority observed in biomechanical strengh between the platelet concentrates utilized 317 
in this study.  318 
 319 
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An important finding was that L-PRF had the greatest number of cells. The significant increase 320 
in the L-PRF group may be artificially elevated because of the presence of leukocytes in the 321 
preparation compared to the control at both day 28 and 42. However, there were quantitatively 322 
more cells in the cartilage interface for L-PRF compared to L- PRP (Figure 4), which suggests 323 
that it may promote cell migration and/or proliferation to a greater extent than L-PRP. The 324 
gelatinous nature of L-PRF may allow for sustained release of growth factors over a greater 325 
period of time when compared to L-PRP and the control. PRF has been previously been shown 326 
to more gradually release growths factors especially in comparison to PRP20,36. Schär et al. 327 
specifically found that more TGF-ß1 and VEGF was released from L-PRF compared with L-328 
PRP. The release of TGF-ß1 was bimodal in nature and peaked at 8 hours and 7 days, while L-329 
PRF had a single higher peak at 7 days. VEGF releas from L-PRP peaked at 8 hours and 3 days 330 
in contrast with L-PRF in which it peaked at 7 days23. This sustained release may also offset the 331 
known catabolic response cells have in response to leukocyte-rich platelet concentrates21 as there 332 
is clearly an increase in cell number in the L-PRF group. This is supported by the fact that IL-1B, 333 
which is known to play a role in inflammation and/or matrix degradation, has been shown to 334 
have a more sustained concentration in L-PRP when compared to L-PRF23. Schär et al. also 335 
found better migration in vitro for MSC and endothelial cells in L-PRF compared to L-PRP23. 336 
Further, even the preparation of PRP can alter the ext nt and duration of cytokine release20 and 337 
as a result, great care must be taken in ensuring the proper protocol is used for L-PRP given the 338 
significant variability in its preparation in the clinical setting. 339 
 340 
Interestingly, our findings demonstrated that L-PRP elicited the greatest amount of sGAG 341 
production. Kazemi et al. found that L-PRF and L-PRP demonstrated similar macroscopic and 342 
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microscopic improvements in articular cartilage defects in a dog model37.  However, it should be 343 
noted that both centrifuge spin velocity and time differed between our study and theirs making it 344 
difficult to truly make comparisons.  345 
 346 
It is important to highlight that although L-PRF seemed to have increased biomechanical 347 
strength and collagen content, such improvements were not seen in sGAG accumulation. Instead, 348 
L-PRF had the lowest amount of sGAG accumulation compared to the control and L-PRP.  This 349 
may be secondary to the fact that  L-PRP and L-PRF  release cytokines and growth factors at 350 
different rates and amounts20,23,36. Histological analysis demonstrated that L-PRP-treated 351 
specimens had more intense Safranin-O staining at day 42 compared to the other two groups. 352 
This finding was expected, as the production of sGAG helps stimulate the production of 353 
proteogylcans38. L-PRP appeared to successfully incorporate  newly-synthesized sGAG into the 354 
matrix in the L-PRP group, resulting in increased staining compared to the HA only group. 355 
Further study is required to identify how these platelet concentrates affect production and 356 
incorporation of a proteoglycan-rich matrix.  357 
 358 
The mechanism for the differences between groups is not known. We hypothesize that the 359 
differences relate to the kinetics of cytokine production and release. The fibrin matrix in the L-360 
PRF may entrap platelets and lead to differences in the kinetics of cytokine release. Schär et al. 361 
have shown that growth factor release is different between L-PRF and L-PRP23. There may also 362 
be differences in the platelet number and platelet activation status between the different 363 
preparations. There are also differences regarding the presence or absence of leukocytes39.  364 
Additionally, given that PRP has a liquid consistency, with media changes there is more likely to 365 
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be an incremental decrease in residual PRP concentratio  in the media. Further studies are 366 
required to identify the underlying biological mechanisms for the observed differences. 367 
 368 
Currently, while a number of strategies have been suggested, there has been no consistent 369 
method for augmenting biological integration of scaffold materials with host cartilage tissue. In 370 
addition to stem cells and/or growth factors used experimentally and clinically, several blood-371 
derived products are currently used in clinical practice for the treatment of articular cartilage 372 
defects. The most well-known and commonly used are the platelet-rich concentrates. They are 373 
prepared by differential centrifugation of autologous whole blood and contain a higher 374 
concentration of platelets compared with whole blood. There is an established minimum number 375 
of required platelets (250,000) to ensure efficacy of PRP by the FDA40, however,  the remains a 376 
wide variety of protocols currently used to create platelet-rich concentrates suggests that the 377 
optimal protocol to promote repair and regeneration of cartilage and other tissues is not yet fully 378 
known.  379 
 380 
Limitations: 381 
This study has a several limitations. We used in vitro analysis only for this study. In cell culture 382 
cells are grown in artificial non-physiological conditions without mechanical stimulation, 383 
limiting the in vivo relevance. Additionally, each group was co-cultured within the same dish, 384 
which may have allowed for additive effects of circulating growth factors or for individual 385 
specimens to influence each other. We did not include gross analysis regarding the extent to 386 
which the defect was filled in our study in that all of the scaffolds remained fully present in the 387 
defects as it takes at least 10 weeks for the scaffolds to dissolve in culture41. In regards to our 388 
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mechanical testing we only measured interfacial shear strength, and we did not evaluate 389 
additional mechanical properties of the new tissue (i.e. compressive modulus).  When evaluating 390 
cellularity via the picogreen assay, we did not specifically investigate chondrocyte proliferation 391 
and migration, both of which are important in evaluating healing cartilaginous tissue. We did not 392 
determine the platelet or leukocyte count for L-PRF. Prior studies have indirectly assessed the 393 
PRF clot platelet count by subtracting the platelet count in the residual serum42. Additionally, the 394 
choice of using a double centrifugation technique for preparing L-PRP can result in an extended 395 
force on the platelets which could possibly alter the microstructure of the platelets24. Finally, this 396 
results of this study may be dampened by use of both vine and human derived factors and its 397 
applicability, however, this methodology has been previously used43,44 and our study has 398 
produced data consistent regarding the ability of L-PRP and L-PRF to facilitate cartilage healing 399 
via a scaffold.  400 
 401 
Conclusions: 402 
Delivery of leukocyte rich platelet concentrates in conjunction with a HA scaffold may allow for 403 
improvements in cartilage healing through different pathways. L-PRF was not superior to L-PRP 404 
in its biomechanical strength suggesting that both treatments may be effective in improving 405 









Table and Figure Legends:  414 
Table 1: Analysis of Biomechanical and Biochemical Data for Day 28 and Day 42; NS = not 415 
significant 416 
Figure 1: In vitro model of cartilage plug with scaffold +/- L-PRP/L-PRF 417 
Figure 2: Photographs of the experimental specimens including: A) osteochondral with punch 418 
biopsy defect, B) hyaluronic acid scaffold punchouts, C) L-PRF after preparation prior to punch 419 
biopsy, D) hyaluronic acid scaffold plug within the d fect of the osteochondral specimen, E) 420 
hyaluronic acid scaffold plug saturated with PRP within the defect of the osteochondral 421 
specimen F) placement of a hyaluronic acid scaffold plug with PRF layered on it within the 422 
defect of the osteochondral specimen  423 
Figure 3: Treatment with L-PRF and L-PRP led to improved maxi um interfacial strength 424 
compared to the control; At day 42 L-PRF demonstrated  maximum interfacial strength was 425 
significantly greater than the control (P = 0.015); (*P <0 .05); Footnote: Two-way ANOVA was 426 
performed with a significance set to P< 0.05   427 
Figure 4: DNA content increased between days 28 and 42 in all groups, with L-PRF having a 428 
significantly larger increase at day 28 (P<0.001) and day 42 (P<0.01); (*P < 0.05; **P <0 .01; 429 
***P < .0001); Footnote: Two-way ANOVA was performed with a significance set to P< 0.05   430 
Figure 5: Total sGAG production increased from day 28 to day42, with L-PRP demonstrating 431 
the greatest production, which a significant increased compared to L-PRF at day 42 (p=0.0095); 432 
(**P <0 .01); Footnote: Two-way ANOVA was performed with a significance set to P< 0.05   433 
Figure 6:  Collagen content was significantly higher in the L-PRF group compared to both the 434 
control and L-PRP groups on day 28 and day 42 (*P < 0.05; **P <0 .01); Footnote: Two-way 435 
ANOVA was performed with a significance set to P< 0.05   436 
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Figure 7: Day 42 Safranin-O histological specimens at 10x original magnification from Left to 437 
Right: L-PRP, L-PRF, Control; All the specimens started to form disorganized cartilage-like 438 
tissue at the edge with ECM deposition with more apparent cellular integration and extracellular 439 
matrix deposition at the edges of the construct in the L-PRP and L-PRF groups. L-PRP group 440 
had the greatest amount of ECM deposition and cellular integration compared to L-PRF and the 441 
control group.  442 
 443 
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Comparison Group 1 / 
Comparison Group 2 
Day 28  
Group 1 Mean ± SD / 
Group 2 Mean ± SD 
 
P-Value 
Day 42  
Group 1Mean ± SD / 
Group 2 Mean ± SD 
 
P-Value 
Interfacial Strength (N)  
L-PRP/L-PRF 1.74±1.1/3.08±1.2 NS 6.58±10.9/10.92±9.3 NS 
L-PRP/HA Only  1.74±1.1/0.63 ±0.3 NS 6.58±10.9/0.66±0.4 0.015 
L-PRF/HA Only  3.08±1.2/0.63 ±0.3 NS 10.92±9.3/0.66±0.4 NS 
DNA Content ( µg) 
L-PRP/L-PRF 124.2±65.8/560.5±142.6 0.0002 589.3±224.2/761.1±270.7 NS 
L-PRP/HA Only  124.2±65.8/191.4±44.6 NS 589.3±224.2/296.4±101.8 0.0125 
L-PRF/HA Only  560.5±142.6/191.4±44.6 0.0015 761.1±270.7/296.4±101.8 <0.0001 
sGAG (µg) 
L-PRP/L-PRF 0.5±1.1/0.0±0.0 NS 16.0±11.5/4.3±7.2 NS 
L-PRP/HA Only  0.5±1.1/2.1±2.5 NS 16.0±11.5/9.7±7.1 NS 
L-PRF/HA Only  0.0±0.0/2.1±2.5 NS 4.3±7.2/9.7±7.1 0.0095 
Collagen  Content ( µg) 
L-PRP/L-PRF 21.1±10.2/31.2±5.3 NS 16.3±7/40.1±9.7 <0.0001 
L-PRP/HA Only  21.1±10.2/17.6± 7.5 NS 16.3±7/20.4±6.8 NS 
L-PRF/HA Only  31.2±5.3/17.6± 7.5 NS 40.1±9.7/20.4±6.8 0.0006 
 
 







